Advertisement

Journal of Neural Transmission

, Volume 104, Issue 2–3, pp 307–310 | Cite as

Inositol treatment of autism

  • J. Levine
  • A. Aviram
  • A. Holan
  • A. Ring
  • Y. Barak
  • R. H. Belmaker
Short Communication Biological Psychiatry

Summary

Recent studies suggest that serotonin reuptake inhibitors are helpful in at least some symptoms of autism. Inositol is a precursor of the second messenger for some serotonin receptors, and has been reported effective in depression, panic disorder and obsessive-compulsive disorder. However a controlled double-blind crossover trial of inositol 200 mg/kg per day showed no benefit in 9 children with autism. Since biochemical studies suggest that inositol may augment serotonin effects, future studies could evaluate inositol in children already receiving serotonin reuptake inhibitors.

Keywords

Autism inositol controlled study 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH (1995) Double blind controlled trial of inositol treatment of panic disorder. Am J Psychiatry 152: 1084–1086PubMedGoogle Scholar
  2. Conners CK (1969) A teacher rating scale for use in drug studies with children. Am J Psychiatry 126: 884–888PubMedGoogle Scholar
  3. Cook EH, Rowlett R, Jaselskis C, et al (1992) Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 311: 739–745Google Scholar
  4. Fux M, Levine J, Aviv A, Belmaker RH (1996) Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 153: 1219–21PubMedGoogle Scholar
  5. Garber HJ, McGonigle JJ, Slomka GT, Monteverde E (1992) Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry 31: 1157–4460PubMedGoogle Scholar
  6. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapaport JL (1993) A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50: 441–447PubMedGoogle Scholar
  7. Hallman M, Bry K, Hoppu K, Lappi M, Pohjavouri M (1992) Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 326: 1233–1239PubMedGoogle Scholar
  8. Levine J, Barak Y, Gonsalves M, Szor H, Elizur A, Kofman O, Belmaker RH (1995) A double-blind controlled trial of inositol treatment of depression. Am J Psychiatry 152: 792–794PubMedGoogle Scholar
  9. Rahman S, Neuman RS (1993) Myo-inositol reduces serotonin (5-HT2) receptor induced homologous and heterologous desensitization. Brain Res 631: 349–351PubMedGoogle Scholar
  10. Schopler E, Reichler RJ, Devellis RF, et al (1980) Toward objective classification of childhood autism: childhood autism rating scale. J Autism Dev Disord 10: 91–103PubMedGoogle Scholar
  11. Vocci FJ, Deutsch SI (1990) Novel drug development in developmental disorders. In: Deutsch SI, Weizman A, Weizman R (eds) Application of basic neuroscience to child psychiatry. Plenum Publishing Corporation, New YorkGoogle Scholar
  12. Zeisel SH (1986) Dietary influences on neurotransmission. Adv Pediatr 33: 23–47PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. Levine
    • 1
  • A. Aviram
    • 2
  • A. Holan
    • 1
  • A. Ring
    • 1
  • Y. Barak
    • 1
  • R. H. Belmaker
    • 3
  1. 1.Abarbanel Mental Health CenterBat Yam
  2. 2.Child Diagnosis and Rehabilitation CenterEdith Wolfson Medical CenterHolon
  3. 3.Ministry of Health Mental Health Center, Faculty of Health SciencesBen Gurion University of the NegevBeershevaIsrael

Personalised recommendations